43
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      C11orf95- RELA fusions drive oncogenic NF-κB signaling in ependymoma

      research-article
      1 , 2 , 3 , 4 , 5 , 1 , 4 , 1 , 2 , 4 , 1 , 4 , 3 , 3 , 3 , 1 , 4 , 1 , 4 , 4 , 2 , 2 , 2 , 6 , 2 , 2 , 2 , 2 , 4 , 1 , 4 , 1 , 1 , 1 , 1 , 4 , 2 , 6 , 1 , 1 , 1 , 7 , 8 , 9 , 10 , 1 , 11 , 12 , 1 , 11 , 1 , 11 , 12 , 1 , 2 , 1 , 11 , 1 , 11 , 12 , 1 , 11 , 12 , 14 , 1 , 11 , 12 , 14 , 1 , 4 , 5 , 1 , 2 , 1 , 4 , 1 , 3
      Nature

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The nuclear factor-κB (NF-κB) family of transcriptional regulators are central mediators of the cellular inflammatory response. Although constitutive NF-κB signaling is present in most human tumours, mutations in pathway members are rare, complicating efforts to understand and block aberrant NF-κB activity in cancer. Here, we show that more than two thirds of supratentorial ependymomas contain oncogenic fusions between RELA, the principal effector of canonical NF-κB signalling, and an uncharacterized gene, C11orf95. In each case, C11orf95-RELA fusions resulted from chromothripsis involving chromosome 11q13.1. C11orf95-RELA fusion proteins translocated spontaneously to the nucleus to activate NF-κB target genes, and rapidly transformed neural stem cells—the cell of origin of ependymoma—to form these tumours in mice. Our data identify the first highly recurrent genetic alteration of RELA in human cancer, and the C11orf95-RELA fusion protein as a potential therapeutic target in supratentorial ependymoma.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.

          Nuclear factor kappaB (NF-kappaB) transcription factors have a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-kappaB and the signalling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemotherapy and radiotherapy. This article discusses recent evidence from cancer genetics and cancer genome studies that support the involvement of NF-kappaB in human cancer, particularly in multiple myeloma. The therapeutic potential and benefit of targeting NF-kappaB in cancer, and the possible complications and pitfalls of such an approach, are explored.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

            Accumulating evidence implicates the transcription factor NF-kappaB as a positive mediator of cell growth, but the molecular mechanism(s) involved in this process remains largely unknown. Here we use both a skeletal muscle differentiation model and normal diploid fibroblasts to gain insight into how NF-kappaB regulates cell growth and differentiation. Results obtained with the C2C12 myoblast cell line demonstrate that NF-kappaB functions as an inhibitor of myogenic differentiation. Myoblasts generated to lack NF-kappaB activity displayed defects in cellular proliferation and cell cycle exit upon differentiation. An analysis of cell cycle markers revealed that NF-kappaB activates cyclin D1 expression, and the results showed that this regulatory pathway is one mechanism by which NF-kappaB inhibits myogenesis. NF-kappaB regulation of cyclin D1 occurs at the transcriptional level and is mediated by direct binding of NF-kappaB to multiple sites in the cyclin D1 promoter. Using diploid fibroblasts, we demonstrate that NF-kappaB is required to induce cyclin D1 expression and pRb hyperphosphorylation and promote G(1)-to-S progression. Consistent with results obtained with the C2C12 differentiation model, we show that NF-kappaB also promotes cell growth in embryonic fibroblasts, correlating with its regulation of cyclin D1. These data therefore identify cyclin D1 as an important transcriptional target of NF-kappaB and reveal a mechanism to explain how NF-kappaB is involved in the early phases of the cell cycle to regulate cell growth and differentiation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300.

              The transcriptional activity of NF-kappa B is stimulated upon phosphorylation of its p65 subunit on serine 276 by protein kinase A (PKA). The transcriptional coactivator CPB/p300 associates with NF-kappa B p65 through two sites, an N-terminal domain that interacts with the C-terminal region of unphosphorylated p65, and a second domain that only interacts with p65 phosphorylated on serine 276. Accessibility to both sites is blocked in unphosphorylated p65 through an intramolecular masking of the N terminus by the C-terminal region of p65. Phosphorylation by PKA both weakens the interaction between the N- and C-terminal regions of p65 and creates an additional site for interaction with CBP/p300. Therefore, PKA regulates the transcriptional activity of NF-kappa B by modulating its interaction with CBP/p300.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                19 May 2014
                19 February 2014
                27 February 2014
                27 August 2014
                : 506
                : 7489
                : 451-455
                Affiliations
                [1 ]St Jude Children’s Research Hospital - Washington University Pediatric Cancer Genome Project, USA
                [2 ]Department of Computational Biology and Bioinformatics, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
                [3 ]Department of Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
                [4 ]Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
                [5 ]Department of Immunology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
                [6 ]Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
                [7 ]Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
                [8 ]Department of Radiological Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
                [9 ]Department of Surgery, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
                [10 ]M D Anderson Cancer Center-Orlando, Pediatric Hematology/Oncology, 92 West Miller MP 318, Orlando, FL 32806
                [11 ]The Genome Institute, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63108, USA
                [12 ]Department of Genetics, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63108, USA
                [13 ]Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63108, USA
                [14 ]Siteman Cancer Center, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63108, USA
                Author notes
                [*]

                These authors contributed equally to the work.

                Article
                NIHMS561293
                10.1038/nature13109
                4050669
                24553141
                0fb93dd2-b8b9-4725-b8c0-2cf62e15f67e
                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article